Healthcare News Pharma Industry News

Gene therapy may be “one shot stop” for rare bone disease

For the last 10 years, the only effective treatment for hypophosphatasia (HPP) has been an enzyme replacement therapy that must be delivered by injection three-to-six times each week.

“It's been a tremendous success and has proven to be a lifesaving treatment,” said José Luis Millán, PhD, professor in the Human Genetics Program at Sanford Burnham Prebys.

For the last 10 years, the only effective treatment for hypophosphatasia (HPP) has been an enzyme replacement therapy that must be delivered by injection three-to-six times each week.

"It's been a tremendous success and has proven to be a lifesaving treatment," said José Luis Millán, PhD, professor in the Human Genetics Program at Sanford Burnham Prebys.

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

Leave a Comment

[mwai_chat window="true" fullscreen="true"]